CNTA · Insider Trading
Centessa Pharmaceuticals plc American Depositary Shares
Every open-market purchase and sale reported by CNTA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Raphael Deferiere | Chief Accounting Officer | D | −11,000 | — |
| 2026-06-24 | Mathias Hukkelhoven | Director | D | −232,000 deriv. | — |
| 2026-06-24 | INDEX VENTURES LIFE VI (JERSEY) L.P. | 10%+ Owner | Sell | −29,885,367 | — |
| 2026-06-24 | Mario Alberto Accardi | Chief Executive Officer | D | −243,282 | — |
| 2026-06-24 | Iqbal J Hussain | Chief Legal Officer | D | −123,145 | — |
| 2026-06-24 | Gregory M Weinhoff | Chief Business Officer | D | −65,925 | — |
| 2026-06-24 | Carol Stuckley | Director | D | −392,474 deriv. | — |
| 2026-06-24 | Arjun Goyal | Director | D | −462,585 | — |
| 2026-06-24 | Mary Lynne Hedley | Director | D | −392,474 deriv. | — |
| 2026-06-24 | Karen M. Anderson | Chief People Officer | D | −62,085 | — |
| 2026-06-24 | Brett I W Zbar | Director | D | −248,570 deriv. | — |
| 2026-06-24 | Francesco De Rubertis | Director | D | −19,963,157 | — |
| 2026-06-24 | Stephen Kanes | Chief Medical Officer | D | −120,000 | — |
| 2026-06-24 | John J Crowley | Chief Financial Officer | D | −45,000 | — |
| 2026-06-24 | Medicxi Ventures I GP Ltd | 10%+ Owner | Sell | −199,631,570 | — |
| 2026-06-24 | Tia L Bush | Chief Technology & Quality Ofc | D | −147,954 | — |
| 2026-06-24 | Samarth Kulkarni | Director | D | −392,474 deriv. | — |
| 2026-05-18 | Mario Alberto Accardi | Chief Executive Officer | F | −604 | −$23.81K |
| 2026-03-27 | Karen M. Anderson | Chief People Officer | MIXED | — | −$908.36K |
| 2026-03-26 | Gregory M Weinhoff | Chief Business Officer | MIXED | — | −$627.55K |
| 2026-03-18 | Karen M. Anderson | Chief People Officer | MIXED | — | −$1.81M |
| 2026-03-16 | Karen M. Anderson | Chief People Officer | MIXED | −10,631 | −$2.71M |
| 2026-03-13 | Karen M. Anderson | Chief People Officer | MIXED | −10,631 | −$2.71M |
| 2026-03-13 | Gregory M Weinhoff | Chief Business Officer | Sell | −73,196 | −$1.93M |
| 2026-02-03 | Stephen Kanes | Chief Medical Officer | A | +120,000 | — |
| 2026-02-03 | Raphael Deferiere | Chief Accounting Officer | A | +11,000 | — |
| 2026-02-03 | Gregory M Weinhoff | Chief Business Officer | MIXED | +16,842 | −$347.86K |
| 2026-02-03 | John J Crowley | Chief Financial Officer | A | +45,000 | — |
| 2026-02-03 | Mario Alberto Accardi | Chief Executive Officer | MIXED | +65,085 | −$71.62K |
| 2026-02-03 | Karen M. Anderson | Chief People Officer | MIXED | +18,394 | −$260.59K |
| 2026-02-03 | Tia L Bush | Chief Technology & Quality Ofc | MIXED | +26,451 | −$210.05K |
| 2026-02-03 | Iqbal J Hussain | Chief Legal Officer | MIXED | +12,259 | −$1.20M |
| 2025-12-09 | Mario Alberto Accardi | President, Orexin Program | Sell | −10,000 | −$288.29K |
| 2025-12-08 | Mario Alberto Accardi | President, Orexin Program | MIXED | −5,000 | −$252.35K |
| 2025-11-18 | Tia L Bush | Chief Technology & Quality Ofc | MIXED | — | −$743.20K |
| 2025-11-18 | Iqbal J Hussain | General Counsel | MIXED | — | −$130.80K |
| 2025-11-13 | Tia L Bush | Chief Technology & Quality Ofc | MIXED | — | −$663.20K |
| 2025-11-03 | Mario Alberto Accardi | President, Orexin Program | F | −593 | −$14.77K |
| 2025-10-27 | Mario Alberto Accardi | President, Orexin Program | MIXED | −3,000 | −$159.95K |
| 2025-10-16 | Iqbal J Hussain | General Counsel | MIXED | — | −$99.40K |
| 2025-09-24 | Tia L Bush | Chief Technology & Quality Ofc | MIXED | — | −$510.30K |
| 2025-09-16 | Mario Alberto Accardi | President, Orexin Program | Sell | −8,172 | −$174.85K |
| 2025-09-15 | Iqbal J Hussain | General Counsel | MIXED | — | −$96.06K |
| 2025-09-11 | Iqbal J Hussain | General Counsel | MIXED | — | −$606.50K |
| 2025-09-11 | Mario Alberto Accardi | President, Orexin Program | MIXED | −2,000 | −$99.95K |
| 2025-09-11 | Tia L Bush | Chief Technology & Quality Ofc | MIXED | — | −$611.76K |
| 2025-08-15 | Iqbal J Hussain | General Counsel | MIXED | — | −$68.34K |
| 2025-08-01 | Mario Alberto Accardi | President, Orexin Program | F | −597 | −$10.25K |
| 2025-07-30 | Mario Alberto Accardi | President, Orexin Program | Sell | −8,322 | −$126.75K |
| 2025-07-25 | Gregory M Weinhoff | Chief Business Officer | MIXED | — | −$117.10K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Saurabh Saha | Chief Executive Officer | 259,017 | $10.49M |
| David M Chao | Chief Administrative Officer | 232,007 | $9.40M |
| Tia L Bush | Chief Technology & Quality Ofc | 3,000 | $121.50K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CNTA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.